Introduction
============

Sturge-Weber syndrome (SWS), also known as encephalofacial angiomatosis, is a congenital neurocutaneous disorder characterized by facial port-wine stains, ipsilateral occipital leptomeningeal angioma and/or abnormal blood vessels in the eyes, which predisposes patients to glaucoma ([@b1-ol-0-0-5791]). SWS occurs in male and female newborns, in 1/20,000 to 1/50,000 live births ([@b2-ol-0-0-5791]). Patients with SWS frequently develop migraines, seizures, stroke-like episodes, hemiparesis, visual problems and mental retardation ([@b3-ol-0-0-5791]). Furthermore, the majority of treatments for the neurological complications associated with SWS are symptomatic instead of radical. The etiology of SWS remains unclear; however, evidence from whole-genome sequencing suggests that somatic mutations in the G protein subunit αq (GNAQ) and RAS p21 protein activator 1 (RASA1) genes are causative factors of SWS and non-syndromic port-wine stains ([@b4-ol-0-0-5791]). Familial SWS is a rare genetic disorder that is dominantly inherited, which could affect family members with similar congenital deformities. To the best of our knowledge, the genetic factors predisposing to familial SWS have previously been unknown; however, systematic analysis of the genetic and molecular mechanisms underlying familial SWS is warranted.

Case report
===========

In the present study, a 4-generation family with a history of SWS was analyzed and demonstrated dominant inheritance of SWS ([Fig. 1](#f1-ol-0-0-5791){ref-type="fig"}). SWS was diagnosed in 3 of the family members (II-1, III-11 and IV-6). The patients\' clinicopathological characteristics are illustrated in [Table I](#tI-ol-0-0-5791){ref-type="table"}. The present study was reviewed and approved by the Ethics Committees of Peking University Shenzhen Hospital (Shenzhen, China) and informed consent was obtained from all patients. To systematically screen for candidate mutations associated with SWS, the full range of exons from the GNAQ and RASA1 genes of all family members were sequenced using Sanger sequencing Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The primer sequences of exons from the GNAQ and RASA1 genes are presented in [Tables II](#tII-ol-0-0-5791){ref-type="table"} and [III](#tIII-ol-0-0-5791){ref-type="table"}.

To identify the candidate mutation, all the genetic variants common to the three patients with SWS were compared with the control data from family member IV-5 ([Fig. 2](#f2-ol-0-0-5791){ref-type="fig"}). A total of 8 case-specific genetic variants that coexisted in the 3 patients were identified. The case-specific variants were subsequently compared with genetic polymorphism datasets from the Single Nucleotide Polymorphism database \[National Center for Biotechnology Information (NCBI); <http://www.ncbi.nlm.nih.gov/projects/SNP/>\] and the 1000 Genome Project database (<http://www.1000genomes.org/>). Following these two comparative steps, a novel candidate mutation, potentially associated with familial SWS, was identified.

According to the NCBI (<http://www.ncbi.nlm.nih.gov/>), the human GNAQ gene is located on chromosome 9q21, and contains 7 exons and 8 introns, encoding guanine nucleotide-binding protein (G protein), q polypeptide (Gαq). As illustrated in [Fig. 2](#f2-ol-0-0-5791){ref-type="fig"}, one non-synonymous single-nucleotide variation (nsSNV) was present exclusively in the 3 patients with SWS. The variation was predicted to be located on the fourth exon of GNAQ and resulted in the substitution of amino acid p.Arg183Gln (p.R183Q). Evolutionary conservation analysis was performed using MegAlign software version 5 (DNASTAR^®^, Inc., Madison, WI, USA). Multiple protein alignments revealed that the Arg183 residue on the GNAQ gene is highly conserved across several vertebrate species ([Fig. 3](#f3-ol-0-0-5791){ref-type="fig"}), which indicates that the p.R183Q mutation is likely to disrupt the normal functions of Gαq. In addition, the functional significance of the SWS-associated mutation was predicted using several complementary nsSNV scoring algorithms, including SIFT ([@b5-ol-0-0-5791]), PolyPhen2 ([@b6-ol-0-0-5791]), PhastCons ([@b7-ol-0-0-5791]) and GERP scores ([@b8-ol-0-0-5791]). As hypothesized, the p.R183Q mutation results in a change to the function of the encoded protein Gαq.

To detect the sub-cellular localization of Gαq, the mutant (R183Q) and wild-type (WT) genotypes of the human GNAQ gene were overexpressed in 293T cells. The cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The coding sequence of human GNAQ (WT) was amplified using reverse transcription-polymerase chain reaction (RT-PCR) analysis with the following primers: Forward, 5′-CCGGAATTCTATGACTCTGGAGTCCATCATGGCGT-3 and reverse,5′-CGCGGATCCACGCCATGATGGACTCCAGAGTCAT-3′. Reverse transcription was performed using a PrimeScript™ Reverse Transcription Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer\'s protocol. The thermocycling conditions were as follows: 37°C for 60 min; 95°C for 5 min; and then held at 4°C. PCR was performed using the Takara EmeraldAmp PCR Master mix (Takara Biotechnology Co., Ltd.). The PCR thermocycling conditions were as follows: 98°C for 2 min, 98°C for 20 sec, 60°C for 30 sec and 72°C for 2 min for 36 cycles, with a final step at 72°C for 5 min. Subsequently, the PCR products were double-digested at 37°C for 60 min using the restriction endonucleases *Eco*RI and *Bam*HI (Takara Bio, Inc., Otsu, Japan), and the digested products were sub-cloned into the plasmid enhanced green fluorescent protein (EGFP)-C1 vector (Thermo Fisher Scientific, Inc.) to produce a pEGFP-C1-GNAQ fusion protein-expressing vector. The coding sequence of EGFP-GNAQ was confirmed through DNA sequencing by Thermo Fisher Scientific, Inc. The GNAQ mutant was synthesized by Thermo Fisher Scientific, Inc. The nuclei of 293T cells were labeled using Hoechst 33258 and normal 293T cells transfected with the empty vector (pEGFP-C1) were used as controls. Immunofluorescence analysis was performed as described previously ([@b9-ol-0-0-5791]). The data showed that the GNAQ (WT) recombinant protein was predominantly detected in the cytoplasm, whereas the GNAQ (R183Q) was mainly detected in the nuclei of the 293T cells ([Fig. 4](#f4-ol-0-0-5791){ref-type="fig"}). This result suggests that the change of subcellular localization contributes to the generation of a loss-of-function Gαq protein. The results of the present study demonstrated that the mutation p.R183Q may be a risk factor that contributes to the pathogenesis of familial SWS.

Discussion
==========

Gαq is a member of the q class of G-protein α subunits that mediates signals between G protein-coupled receptors (GPCRs) and downstream effectors. GPCRs are involved in RAS-associated signaling pathways. Gαq Arg183 is conserved in the GTP-binding pocket of all human Gα subunits, which serves an essential role in the hydrolysis of GTP. Results from previous studies have demonstrated that substituting Arg183 with a cysteine residue reduces the intrinsic GTPase activity and increases the signaling activity ([@b10-ol-0-0-5791]--[@b12-ol-0-0-5791]). The p.R183Q mutation identified in the present study is located in the GTP-binding domain of GNAQ. Therefore, it was hypothesized that the substitution of arginine with glutamine affects the functions of Gαq by changing its subcellular localization.

Previous studies have established that activating mutations in genes that encode Gα subunits are associated with various diseases, including McCune-Albright syndrome, which exhibits characteristic skeletal abnormalities and abnormal skin pigmentation ([@b13-ol-0-0-5791]). Activating GNAQ mutations have been found in patients with blue nevi and nevi of Ota ([@b14-ol-0-0-5791]). In addition, GNAQ mutations were previously identified in a chemical mutagenesis screen for a dark-skin phenotype in laboratory mice ([@b15-ol-0-0-5791]). An activating GNAQ mutation may have oncogenic functions ([@b16-ol-0-0-5791]). The results of several studies revealed that mutations in the Q209 and R183 residues of the GNAQ gene, including the Q209L substitution located in the Ras-like domain, are likely to exhibit involvement in the process of tumorigenesis via the upregulation of the mitogen-activated protein kinase pathway ([@b16-ol-0-0-5791]). R183 is located in the GTP-binding pocket of the Gα subunit and has an important role in GTP hydrolysis; however, a markedly lower potential to activate signal transmission was found for the R183 mutant compared with the Q209 mutant ([@b17-ol-0-0-5791],[@b18-ol-0-0-5791]).

In the current study, the R183Q mutation of the GNAQ gene was identified as a potential cause for familial SWS through the sequencing of all of the exons of the GNAQ and RASA1 genes in 3 patients with familial SWS. The functional study confirmed that the genetic mutation R183Q affected the functions of the encoded protein, Gαq. To the best of our knowledge, this is the first genetic mutation to be associated with the pathogenesis of familial SWS. The results of the present study, in addition to data from previous studies, suggest that an imbalance in the hydrolysis of GTP is the common cause of certain congenital neurocutaneous disorders, such as SWS. These findings may aid in the development of novel diagnostic markers and/or therapeutic targets for the treatment of patients with familial SWS.

The present study was supported by the Shenzhen Project of Science and Technology (grant no. 20130309175830). The experiments were performed at The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics (Peking University Shenzhen Hospital, Shenzen, China).

![A 4-generation family tree of familial Sturge-Weber syndrome. Black boxes represent the affected individuals. The arrow beside the black box indicates the proband.](ol-13-04-2665-g00){#f1-ol-0-0-5791}

![A missense mutation in the G protein subunit αq gene identified in patients with familial SWS. Trace chromatograms were developed using Sanger sequencing and revealed a validated missense mutation (p.R183Q). The three upper panels illustrate the sequencing chromatograms of the patients with familial, SWS II-1, III-11 and IV-6, while the lower panel illustrates the sequencing chromatogram of the control group, IV-5. SWS, Sturge-Weber syndrome.](ol-13-04-2665-g01){#f2-ol-0-0-5791}

![Evolutionary conservation analysis of amino acids affected by the missense mutation. The identification numbers of guanine nucleotide-binding protein (G protein), q polypeptide were as follows: Human (NP_0,02063.2), Chimpanzee (XP_0,033,12167.1), Rhesus (XP_0,011,00833.1), Bovine (NP_0,011,03472.1), Rat (NP_112,298.1) and Mouse (NP_03,2165.3). The mutant alleles are boxed, and the asterisk (\*) shows the conserved residue.](ol-13-04-2665-g02){#f3-ol-0-0-5791}

![Immunolocalization analysis of GNAQ (WT) and GNAQ (R183Q) in transfected 293T cells. Green represents the anti-GNAQ staining, nuclei were stained with Hoechst 33,258. Cells were transfected with plasmid DNA (pEGFP-C1 vector) encoding the GNAQ (WT) or GNAQ (R183Q). Normal 293T cells transfected with the empty vector (pEGFP-C1) served as controls. Cells transfected with GNAQ (WT) illustrated GNAQ recombinant protein expression predominantly in the cytoplasm, whereas expression of the GNAQ recombinant protein from the GNAQ (R183Q) transfected cells was mainly detected as patches distributed across the entire nucleus. Scale bar, 10 µm. GNAQ, G protein subunit αq; WT, wild-type; R183Q, p.Arg183Gln; EGFP, enhanced green fluorescent protein; NC, normal control.](ol-13-04-2665-g03){#f4-ol-0-0-5791}

###### 

Clinicopathological characteristics of the 3 patients with SWS from the 4-generation family.

  Family member   Gender   Age, years   Presence of SWS   Location     Size, cm
  --------------- -------- ------------ ----------------- ------------ ----------
  I-1             M        74           No                             
  I-2             F        68           No                             
  I-3             M        73           No                             
  I-4             F        70           No                             
  II-1            M        52           Yes               Right arm    2
  II-2            F        48           No                             
  III-1           M        51           No                             
  III-2           F        55           No                             
  III-3           M        39           No                             
  III-4           F        42           No                             
  III-5           M        36           No                             
  III-6           F        37           No                             
  III-7           M        36           No                             
  III-8           F        38           No                             
  III-9           M        37           No                             
  III-10          F        35           No                             
  III-11          M        37           Yes               Left arm     2
  III-12          F        38           No                             
  IV-1            M        24           No                             
  IV-2            M        12           No                             
  IV-3            F        10           No                             
  IV-4            F          8          No                             
  IV-5            M          8          No                             
  IV-6            M          7          Yes               Right face   4

SWS, Sturge-Weber syndrome; M, male; F, female.

###### 

Primer sequences for reverse transcription-polymerase chain reaction amplification of G protein subunit αq exons.

  Exon   Forward primer sequence (5′-3′)   Reverse primer sequence (5′-3′)   Size, bp
  ------ --------------------------------- --------------------------------- ----------
    1    AGACTATCCGCTCCCACCGC              GCCTCTGGTCGGAGTGATCTGC            694
    2    CATAGGTAGTGTTTCCAATTCTAGA         ATGATACTTACAAACTCTCTCCTTA         660
    3    AAGGAAGGTGTTACCTGAATTGTA          TTAGATTTATGAGGTTGGCATAAG          420
    4    ATGTAATCCATAGATGGATAACCTT         TTGTTTTGAAGCCTACACATGATT          430
    5    GTATTAATTGAATTGACTTGGATGA         TCAGAACCTCTGCATAGTGTTA            514
    6    ATGACAGTGTTCCAGATTCACAAC          ACACTGGGGTTTGGAGACAAAAC           530
    7    TTCATGAGCAATGACACAGTATTT          GACGGCAATAAATTAGTATTATGC          398

###### 

Primer sequences for reverse transcription-polymerase chain reaction amplification of RAS p21 protein activator 1 exons.

  Exon   Forward primer sequence (5′-3′)   Reverse primer sequence (5′-3′)   Size, bp
  ------ --------------------------------- --------------------------------- ----------
    1    GAGTAGAGCGGGCTTCAACATGA           GGAGCCAGCTTCCCAAATTCCTGA          600
    2    GGCATTTAAAACCTCTAGTAGTAT          TAAATATATTTGAGGATCAGCACAG         480
    3    TAGCCCCAAGTAATTTACTGTGAT          ATTTCAGAATCTTGCAGCAAAGTC          630
    4    GGCACTGGGTATTTATAGTCCAAG          GTGAGAGACAGTGGAATAAAACC           475
    5    ACTCTAATTCCTTACATTTTTCAAT         TTATAATATGCTAGCCTGATTATGT         420
    6    TTAAGAGAGGTTTGGAAAGATATT          GAGTAAGAGAGAATTGGGATTAAT          690
    7    AGACCTATAACAGTCTGTTATTATC         TCACCTAGTGTTACTTCTGAG             590
    8    AAGCTGGTAAGATACACCAGAGA           GACACTGTCTAAAGAATTCTTGGG          539
    9    CTTGATGGGTATGGAAAATCAGAA          AGGTTGTTCCTGATTACCTAAAATC         520
  10     CTTTGGAAAGCAAAAGATCATTTA          ATGCTTATATATGGGCTCTAAACAA         410
  11     AGGCATTTTTGTACAGATTTGTTAT         AAGTGCATCTGCTACTTTTAGAAG          449
  12     ACTGATAACATTTTAATAGTGCTG          AGGTCAATTTAAAATGGAGTTTTC          527
  13     TGAGAATAGAAATGGCAGTCTAG           TTTCATAAAGAAGTAACGTTTTCCT         360
  14     ATGTCTGAATGTTTTAAGTATGTC          GCTATTAGAACACCTGGATATGGTA         460
  15     GAGGTTAAAGATGGTAGGAAAAG           TAACAGTGTGTACAGTTGAACCAT          500
  16     CTCTCTACCTATCAGAGTTTAGTG          GTGCTACTAAGCTATGAATTACTAT         480
  17     AATGATGCCAGAGATTTTAAACCT          TTGTGGCTTCTAGTACTTATCTGC          600
  18     CATTGTAATTAGTACTTTCAACGC          AATTTCTGGTGCAACTTGATGG            518
  19     GGCTAATTGGGAATAAATGGTAAC          ACCATGACTTTTTCAGAGTATAATA         450
  20     ATAAAGTTTTCCTTACCCCTTGCT          GCCTCATCTTGTAAGGGTTTAA            519
  21     GGTTTAGAGTGAATTTTATGGGTT          GGTTTGAGACACAAATAGGGGTA           462
  22     ACATTCTGAGTTCCGAATGGAAG           CTTTCATCGCTAAAAATTTCACTGC         335
  23     TGTGTTGCTGCTGCTACACCTAAT          AAGGCAGACAAAAATTTGCAGGC           400
  24     ATGTGAATACAAAGGTTACAAAGT          CAGACTCAAGAGCAAAACCTGAT           744
  25     GAATTGTGGTAATATTTTATGCATC         CAGATAGCTTACAAGGTTGCTG            395
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